Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Biomedicines|October 28, 2023
Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric SurgeryMiguel A Rubio-Herrera, Sara Mera-Carreiro, Andrés Sánchez-Pernaute, et al.
Endocrinologia, Diabetes Y Nutricion|June 19, 2018
Nivolumab-induced thyroid dysfunction in patients with lung cancerAna M Ramos-Levi, Jacobo Rogado, Jose Miguel Sanchez-Torres, et al.
BMC Surgery|March 30, 2013
Which criteria should be used to define type 2 diabetes remission after bariatric surgery?Ana M Ramos-Levi, Lucio Cabrerizo, Pilar Matía, et al.
Endocrine|July 3, 2017
Pathogenic Th17 and Th22 cells are increased in patients with autoimmune thyroid disordersMarlen Vitales-Noyola, Ana M Ramos-Levi, Rebeca Martínez-Hernández, et al.
The Journal of Clinical Endocrinology and Metabolism|July 9, 2018
Patients With Autoimmune Thyroiditis Show Diminished Levels and Defective Suppressive Function of Tr1 Regulatory LymphocytesMarlen Vitales-Noyola, Ana Serrano-Somavilla, Rebeca Martínez-Hernández, et al.
Journal of Diabetes|January 18, 2014
Statistical models to predict type 2 diabetes remission after bariatric surgeryAna M Ramos-Levi, Pilar Matia, Lucio Cabrerizo, et al.
The Journal of Clinical Endocrinology and Metabolism|November 18, 2016
Expression and Function of the Costimulatory Receptor SLAMF1 Is Altered in Lymphocytes From Patients With Autoimmune ThyroiditisMarlen Vitales-Noyola, Ana M Ramos-Levi, Ana Serrano-Somavilla, et al.
Obesity Surgery|July 30, 2013
Remission of type 2 diabetes mellitus should not be the foremost goal after bariatric surgeryAna M Ramos-Levi, Andres Sanchez-Pernaute, Lucio Cabrerizo, et al.
Journal of Clinical Medicine|July 14, 2023
Mixed Meal Tolerance Test Versus Continuous Glucose Monitoring for an Effective Diagnosis of Persistent Post-Bariatric HypoglycemiaAna M Ramos-Levi, Miguel A Rubio-Herrera, Pilar Matía-Martín, et al.
Oncotarget|December 18, 2015
Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumorsMiguel Sampedro-Núñez, Raúl M Luque, Ana M Ramos-Levi, et al.
Pageof 2